Our Mission
Pioneering precision immune tolerance
Aiming to restore natural immune system balance by re-imagining immunotherapy for autoimmune disease, unlocking the potential of gene therapy and amplifying the efficacy of biologic therapy.
Our Purpose
Selecta Biosciences is a clinical stage biotechnology company with a commitment to solving the challenges associated with autoimmunity and unwanted immunogenicity through our pioneering ImmTOR® precision immune tolerance platform.
Our Platform
ImmTOR® Precision Immune Tolerance Platform
We believe our clinically validated ImmTOR® platform has broad applicability and allows us to develop antigen-specific tolerogenic therapies that may selectively mitigate unwanted immune responses. When ImmTOR® is combined with an engineered, Treg selective IL-2 to make ImmTOR-IL™, the magnitude and durability of antigen-specific immune tolerance may be further amplified. We are investigating the potential of ImmTOR® and ImmTOR-IL™ in overcoming autoimmunity and unwanted immunogenicity.
Portfolio
Leveraging our ImmTOR®/ImmTOR-IL™ platform across autoimmune disease, gene therapy and biologic therapy
The potentially broad applicability of ImmTOR® and ImmTOR-IL™ gives us the opportunity to restore natural immune system balance by re-imagining immunotherapy for autoimmune disease, unlocking the potential of gene therapy and amplifying the efficacy of biologic therapy.
About Us
Developing precision immune tolerance therapies
We are an experienced and diverse team of scientists, physicians, and biotech experts all working toward restoring natural immune system balance by re-imagining immunotherapy for autoimmune disease, unlocking the potential of gene therapy and amplifying the efficacy of biologic therapy.
Join our Team
Selecta is at the cutting edge of precision immune tolerance. ImmTOR® and ImmTOR-IL™ have the potential to transform the treatment of autoimmune disease, gene therapy paradigms and biologic therapy.